The abstract is read at the publisher; the summary is JClub's.
Seventy BRCA2 DNA-binding domain hypomorphic missense variants reduce homologous recombination and cell survival, with 34 strong hypomorphs linked to moderate female breast cancer risk.
- Why it matters: Improved hereditary cancer risk estimation needs functional and clinical classification for reduced-penetrance BRCA2 missense variants.
- What they did: The study tested 70 candidate hypomorphic missense variants for RAD51 foci formation, homologous recombination activity, endogenous cell survival, and PARP inhibitor sensitivity, then integrated functional data into a ClinGen BRCA1/2 curation model.
- The result: Thirty-four strong hypomorphs showed moderate risks and later diagnosis ages than pathogenic variants, and 14 were classifiable as likely pathogenic; tumors with hypomorphic variants had 32% HRD versus 83% with PVs and 7% with benign variants.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.